Originally posted by scout41
NANT TNBC and head and neck data
Results
To date, 3 patients with 3rd-line or greater TNBC and 2 patients with 4th-line or greater HNSCC have been treated with the NANT Cancer Vaccine. All treatment was completed in the outpatient setting, with no immune-related adverse events. Two of the three patients with TNBC experienced partial response (78% and 62% decrease by irRC). Both patients with HNSCC experienced objective tumor response (100% and 47% decrease by irRC). Four hematologic DLT’s were observed and managed with a planned dose reduction of cisplatin. All responding patients are still
undergoing therapy.
Conclusions
This preliminary data suggests that the NANT Cancer Vaccine of low-dose chemoradiation combined with innate and adaptive immunotherapy can be administered safely in an outpatient setting without any observed increased irAE’s. Preliminary efficacy result of four out of five patients (80%) with confirmed overall responses, with one of these four patients demonstrating a complete response with 5th-line metastatic disease is encouraging.
Awesome find scout. My only fear is given the small “n” number, the response may be mediocre. The results are positive, but extremely narrow. The Nasdaq hasn’t even budged with this so far, so let’s see what happens at the AGM.
